PatientsVille.com Logo

CARDIOMEGALY and RIBASPHERE

PatientsVille

CARDIOMEGALY Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for CARDIOMEGALY

CARDIOMEGALY treatment research studies

RIBASPHERE clinical trials, surveys and public health registries


Find Drug Side Effect reports



RIBASPHERE Side Effects

Fatigue (131)
Anaemia (129)
Depression (100)
Asthenia (95)
Dyspnoea (84)
Nausea (82)
Dizziness (67)
White Blood Cell Count Decreased (63)
Dehydration (62)
Headache (58)
Diarrhoea (53)
Vomiting (52)
Weight Decreased (51)
Anxiety (49)
Alopecia (49)
Insomnia (46)
Condition Aggravated (43)
Platelet Count Decreased (35)
Anger (34)
Chest Pain (34)
Arthralgia (34)
Haemoglobin Decreased (33)
Decreased Appetite (33)
Influenza Like Illness (31)
Pneumonia (30)
Red Blood Cell Count Decreased (29)
Pain (29)
Loss Of Consciousness (29)
Back Pain (28)
Anorexia (27)
Chills (26)
Rash (25)
Fall (25)
Blood Glucose Increased (25)
Crying (25)
Cough (24)
Suicidal Ideation (22)
Pyrexia (21)
Abdominal Pain (21)
Hypertension (21)
Feeling Abnormal (20)
Abdominal Pain Upper (19)
Disturbance In Attention (19)
Blood Potassium Decreased (19)
Irritability (17)
Pregnancy (16)
Confusional State (16)
Paranoia (16)
Myalgia (15)
Pruritus (15)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

CARDIOMEGALY Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy
Condition: Cardiomegaly
Intervention: Drug: MEK162
Outcome Measures: Change from baseline in Left ventricular mass (LVM);   Change from baseline in Cardiac energetics state at 3 months and 6 months;   Number of patients with adverse events, serious adverse events and death;   Pharmacokinetics of MEK162 and metabolite (AR00426032): The trough plasma concentration (Ctrough) just prior to drug administration;   Pharmacokinetics of MEK162 and metabolite (AR00426032): maximum drug exposure of MEK162 and its metabolite (AR00426032) in plasma;   Pharmacokinetics of MEK162 and metabolite (AR00426032): time to reach peak concentration (Tmax) in plasma;   Pharmacokinetics of MEK162 and metabolite (AR00426032): Area under the plasma concentration-time profile from time zero to 12 hours post dose (AUC0-12h);   Pharmacokinetics of MEK162 and metabolite (AR00426032): Area under the plasma concentration-time profile from time zero to the last quantifiable sample (AUClast);   Pharmacokinetics of MEK162 and metabolite (AR00426032): accumulation ratio (Racc);   Pharmacokinetics of MEK162: The degree of fluctuation of MEK162 and its metabolite (AR00426032) in plasma at steady state (on Day 8);   Pharmacokinetics of MEK162: The ratio of Metabolite (AR00426032) to MEK162 in plasma on Days 1 and 8;   Change from baseline in end systolic and end diastolic right and left vetricular volumes in 3 and 6 months;   Pharmacokinetics of MEK162 and metabolite (AR00426032):observed maximum plasma concentration (Cmax) following drug adminstration;   Change from baseline in stroke volume and stroke output during 3 and 6 months;   Ejection fraction;   Cardiac index
2 Unknown  Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
Conditions: Acromegaly;   Heart Failure;   Hypertrophy, Left Ventricular
Intervention: Drug: pegvisomant
Outcome Measures: Change in peak systolic strain rate (SRSYS) determined by Color Doppler Myocardial Imaging (CDMI).;   Ejection fraction,Enddiastolic thickness of the infero-lateral wall,Diastolic function,Left ventricular mass index,Stroke volume,Ejection fraction (MRI),CO,Late hyperenhancement,IGF-I,insulin sensitivity,Ringsize,adverse events,Endothelial function
3 Unknown  Left Ventricular Pacing to Avoid Cardiac Enlargement Study
Conditions: Complete Atrioventricular Block;   Sick Sinus Syndrome
Interventions: Device: LV pacing;   Device: RV pacing
Outcome Measures: Left ventricular ejection fraction (%) at 12 months;   Left ventricular end-systolic volume (ml) at 12 months;   Left ventricular end-diastolic volume (ml) at 12 months;   Maximal oxygen uptake (ml/kg min) at 12 months
4 Recruiting Stem Cell Therapy in Patients With Severe Heart Failure & Undergoing Left Ventricular Assist Device Placement
Condition: Heart Failure
Intervention: Biological: Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells
Outcome Measures: Safety of cell delivery;   Improvement in myocardial viability by PET/CT scan;   Combined end points of death and re-hospitalization;   Hemodynamic parameters at baseline and with weaning of LVAD;   Reduction in left ventricular dimensions;   Histological assessment:
5 Recruiting 123I-mIBG SPECT Imaging
Conditions: Heart Failure;   Coronary Artery Disease
Intervention: Drug: Radioisotope
Outcome Measures: Comparison of heart to calibration ratios (HCR) in planar, conventional SPECT and CZT SPECT imaging;   123I-mIBG clearance rates
6 Recruiting Cardiac Allograft Remodeling and Effects of Sirolimus
Conditions: Cardiac Hypertrophy;   Immunosuppression
Interventions: Radiation: Cardiac MRI;   Procedure: Coronary angiography with IVUS;   Other: Cardiac Allograft Remodeling;   Drug: M-TOR Immunosuppression;   Procedure: Cardiac Biopsy C4D stain;   Genetic: Genetic Mechanism of M-TOR;   Other: Cardiopulmonary Exercise Test (CPET)
Outcome Measures: Assessment in left ventricular hypertrophy;   Assess outcomes;   Access outcomes
7 Recruiting Optimizing Left Ventricular Lead To Improve Cardiac Output
Conditions: Ischemic Congestive Cardiomyopathy;   Dilated Cardiomyopathy;   Congestive Heart Failure
Interventions: Procedure: Doppler flow measurement;   Procedure: standard implantation of the LV lead
Outcome Measures: Change in Left Ventricular End Systolic Volume (LVESV) using the difference from baseline to six months;   Change in End diastolic volume;   Change in ejection fraction;   Increase in exercise capacity;   Decrease in heart failure related hospital admissions
8 Recruiting Randomized Comparison of Endocardial Versus Epicardial - From the Coronary Sinus - Left Ventricular Pacing for Resynchronization in Heart Failure.
Conditions: Heart Failure;   Cardiomyopathy, Dilated;   Coronary Disease
Interventions: Device: Resynchronization using a transeptal approach;   Device: Resynchronization using a coronary sinus approach
Outcome Measures: the acute hemodynamic response judged by dP/dt max;   Implant success rate;   number of left ventricular pacing sites assessed;   Pacing Procedure duration;   Per and post implantation complications rate;   Post implantation echocardiography comparing spontaneous rhythm and biventricular pacing for left ventricle ejection fraction;   Post implantation echocardiography comparing spontaneous rhythm and biventricular pacing for mitral regurgitation;   Post implantation echocardiography comparing spontaneous rhythm and biventricular pacing for atrioventricular asynchronism;   Post implantation echocardiography comparing spontaneous rhythm and biventricular pacing for inter and intra-ventricular asynchronism;   sensing performances of left ventricle pacing leads;   pacing threshold performances of left ventricle pacing leads;   impedances performances of left ventricle pacing leads;   Complications rate at 6 month Follow up;   Clinical benefit at 6 month Follow up: Gain in NYHA;   Clinical benefit at 6 month Follow up: 6 minutes walk test;   Clinical benefit at 6 month Follow up: quality of life questionnaire as compared to pre implantation;   Echocardiography at 6 month Follow up: as compared to pre implantation for Left Ventricular Ejection Fraction;   Echocardiography at 6 month Follow up: as compared to pre implantation for Left Ventricle volumes;   Echocardiography at 6 month Follow up: as compared to pre implantation for mitral regurgitation;   Echocardiography at 6 month Follow up: as compared to pre implantation for atrioventricular asynchronism;   Echocardiography at 6 month Follow up: as compared to pre implantation for inter and intra-ventricular asynchronism;   sensing performances of Left Ventricle pacing leads at 6 month Follow up;   pacing threshold performances of Left Ventricle pacing leads at 6 month Follow up;   impedances performances of Left Ventricle pacing leads at 6 month Follow up
9 Recruiting Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy
Conditions: Dilated Cardiomyopathy;   Heart Failure
Interventions: Drug: Qiliqiangxin capsule;   Drug: Placebo
Outcome Measures: The value of left ventricular end-diastolic dimension (LVEDd) and left ventricular ejection fraction(LVEF) confirmed by ultrasonic cardiogram (UCG);   The levels of serum representative cytokines detected by ELISA;   Heart failure aggravation;   All cause mortality;   Sudden cardiac death;   Stroke;   The dynamic changes of serum representative cytokines detected by ELISA in the treatment group
10 Recruiting Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan
Conditions: Renal Failure;   Left Ventricular Hypertrophy
Intervention: Drug: losartan
Outcome Measure: left ventricular hypertrophy
11 Unknown  Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy
Conditions: Myocardial Reperfusion Injury;   Cardiac Output, Low;   Hypertrophy, Left Ventricular
Interventions: Drug: Perhexiline;   Drug: Placebo marked PEXSIG
Outcome Measures: Absolute difference in Cardiac Index (>0.3 l/min/m2);   Incidence of Low Cardiac Output Syndrome;   Incidence of inotrope use according to protocol;   Peak and total release of Troponin
12 Recruiting Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy
Conditions: Dilated Cardiomyopathy;   Chronic Heart Failure
Interventions: Procedure: Intramyocardial injection;   Procedure: Intracoronary injection
Outcome Measures: Changes in left ventricular ejection fraction and dimensions;   Changes in exercise capacity;   Change in NT-proBNP levels
13 Recruiting Impact of Physical Activity on Left Ventricular Mass and Lipid Metabolism
Condition: Left Ventricular Hypertrophy
Intervention: Other: Exercise training, women, marathon
Outcome Measures: Lipid Metabolism;   Heart architecture and function
14 Recruiting A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy
Condition: Dilated Cardiomyopathy
Intervention: Drug: Ranolazine
Outcome Measures: Myocardial perfusion;   Excercise capacity;   Left ventricular systolic and diastolic function;   Supraventricular and ventricular arrhythmias
15 Recruiting Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)
Conditions: Heart Failure With Preserved Ejection Fraction;   Pulmonary Disease;   Left Ventricular Hypertrophy/Hypertension
Interventions: Drug: Dobutamine;   Drug: Amlodipine
Outcome Measures: Change in ejection fraction with 5mcg/kg/min dobutamine;   Change in pulse wave velocity
16 Recruiting PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors
Condition: Dilated Cardiomyopathy
Interventions: Drug: perindopril;   Drug: placebo
Outcome Measures: Change in left ventricle diameter / volume / ejection fraction;   Echocardiographic deterioration of LVEDD or Ejection fraction;   MRI - deterioration of LVEDVol or Ejection fraction;   Occurence of DCM (Echo: EF< 45% and LVEDD>112%, ref Mahon, 2005);   Deterioration of other Echocardiographic parameters;   Deterioration of hormonal biomarkers in serum;   Clinical end-point;   Clinical end-point: death
17 Recruiting Brain Function and Perfusion in Patients With Heart Failure
Conditions: Heart Failure;   Dilated Cardiomyopathy;   Perfusion;   Cognitive Impairment;   Cerebral Hypoperfusion
Intervention:
Outcome Measures: Determinants of cerebral impairment;   Prevalence of cognitive impairment;   Relation of cognitive impairment with local perfusion;   Relation of cognitive impairment with the severity of heart failure;   Relation of cognitive impairment with cardiac output;   Relation of cognitive impairment with the severity of congestion;   Relation of cognitive impairment with the decrease in cerebral perfusion;   The difference of cognitive domains in above relations
18 Unknown  The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy
Conditions: Muscular Dystrophy;   Dilated Cardiomyopathy;   Heart Failure
Intervention:
Outcome Measure:
19 Unknown  Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
Condition: Dilated Cardiomyopathy
Interventions: Biological: CD34+ autologous stem cell transplantation;   Drug: Bone Marrow Stimulation
Outcome Measures: Heart failure mortality;   Changes in exercise capacity;   Changes in electrophysiologic properties of ventricular myocardium;   Changes in plasma inflammatory markers;   Changes in left ventricular function
20 Recruiting PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)
Condition: Non-ischemic Dilated Cardiomyopathy
Interventions: Procedure: Transendocardial injection;   Biological: Autologous hMSCs;   Biological: Allogeneic hMSCs
Outcome Measures: Incidence of any treatment-emergent serious adverse events (TE-SAEs);   Measurement of Changes in Regional Left Ventricular function